M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pelvic Fractures and Radiation Therapy for Cervical Cancer

Conditions: Cervical Cancer
Endometrial Cancer
Vaginal Cancer

Interventions: Procedure: CT or MRI + Blood Test

First Posted Date: 2008-12-02

Last Posted Date: 2020-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 239

Registration Number: NCT00800644

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use

Conditions: Tobacco Use Disorder
Head and Neck Cancer

Interventions: Behavioral: smoking cessation intervention
Other: questionnaire administration
Other: counseling intervention
Other: preventive intervention

First Posted Date: 2008-12-01

Last Posted Date: 2018-11-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 370

Registration Number: NCT00799669

Quality of Life After Esophagectomy for Cancer

Completed

Conditions: Esophageal Cancer

Interventions: Behavioral: Telephone Questionnaire

First Posted Date: 2008-11-26

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 88

Registration Number: NCT00798746

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis

Terminated

Conditions: Prostate Cancer

Interventions: Behavioral: Group Meetings
Behavioral: Questionnaire

First Posted Date: 2008-11-26

Last Posted Date: 2019-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 240

Registration Number: NCT00798187

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2008-11-20

Last Posted Date: 2018-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 66

Registration Number: NCT00794820

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue

Phase 2

Completed

Conditions: Leukemia
CLL

Interventions: Drug: Lenalidomide

First Posted Date: 2008-11-17

Last Posted Date: 2021-07-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00792077

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Decitabine
Drug: Pegylated Interferon Alpha-2b

First Posted Date: 2008-11-14

Last Posted Date: 2018-11-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT00791271

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer

Active, not recruiting

Conditions: Cervical Carcinoma
Vulvar Carcinoma
Endometrial Carcinoma
Malignant Female Reproductive System Neoplasm
Vaginal Carcinoma

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2008-11-14

Last Posted Date: 2024-03-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 79

Registration Number: NCT00791635

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Bendamustine in Acute Leukemia and MDS

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia

Interventions: Drug: Bendamustine

First Posted Date: 2008-11-14

Last Posted Date: 2012-12-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00790855

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma

Phase 2

Terminated

Conditions: Glioblastoma

Interventions: Drug: Placebo
Drug: Aspirin

First Posted Date: 2008-11-13

Last Posted Date: 2011-12-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00790452

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy